Status:
COMPLETED
Efficacy of Thymosin alpha1 for Severe Sepsis
Lead Sponsor:
Sun Yat-sen University
Conditions:
Severe Sepsis
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the efficacy of thymosin alpha 1 for treating severe sepsis.
Detailed Description
Severe sepsis is a disease of infectious origin with a high risk of death. Over the past decade, thymosin alpha1 have already provided clinicians with additional weapon in the fight against infectious...
Eligibility Criteria
Inclusion
- Severe sepsis according to ACCP/CCM criteria
- Patient or legally authorized representative able to provide informed consent
Exclusion
- Subject is less than 18 years or more than 85 years of age
- If female, the subject is pregnant or nursing
- Subject is receiving immunosuppressive therapy such as cyclosporine, azothioprine,or cancer-related chemotherapy
- Patient not expected to survive 28 days because of uncorrectable medical condition, such as poorly controlled neoplasm or other end-stage disease
- History of bone marrow, lung, liver, pancreas, or small-bowel transplantation
- Acute pancreatitis with no established source of infection
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
366 Patients enrolled
Trial Details
Trial ID
NCT00711620
Start Date
May 1 2008
End Date
January 1 2011
Last Update
June 14 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University
Guangzhou, Guangdong, China, 510080